Casdin Capital, LLC Buys Codexis Inc, Invitae Corp, Adaptive Biotechnologies Corp, Sells BeiGene, Evolent Health Inc, Gilead Sciences Inc

• New Purchases: ADPT, ALEC, TWST, TPTX, STOK, ORTX,
• Added Positions: CDXS, NVTA, ALNY, BPMC, AGIO, FIXX, GRTS, DNLI, MGTA, SGMO, SRPT, BLUE,
• Reduced Positions: ONCE, BOLD, CNST,
• Sold Out: BGNE, EVH, GILD,

For the details of Casdin Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/casdin+capital%2C+llc/current-portfolio/portfolio

1. Spark Therapeutics Inc (ONCE) - 884,800 shares, 8.48% of the total portfolio. Shares reduced by 5.87%
2. Invitae Corp (NVTA) - 3,838,388 shares, 8.44% of the total portfolio. Shares added by 74.47%
3. Blueprint Medicines Corp (BPMC) - 940,000 shares, 8.30% of the total portfolio. Shares added by 10.76%
4. Codexis Inc (CDXS) - 5,073,780 shares, 8.10% of the total portfolio. Shares added by 150.56%
5. Sage Therapeutics Inc (SAGE) - 400,000 shares, 6.85% of the total portfolio.

Casdin Capital, LLC initiated holding in Adaptive Biotechnologies Corp. The purchase prices were between $40.3 and $48.3, with an estimated average price of $44.3. The stock is now traded at around $46.93. The impact to a portfolio due to this purchase was 1.88%. The holding were 463,125 shares as of .

Casdin Capital, LLC initiated holding in Alector Inc. The purchase prices were between $16.26 and $26.42, with an estimated average price of $20.32. The stock is now traded at around $15.84. The impact to a portfolio due to this purchase was 0.95%. The holding were 551,039 shares as of .

Casdin Capital, LLC initiated holding in Twist Bioscience Corp. The purchase prices were between $21.74 and $33.2, with an estimated average price of $26.5. The stock is now traded at around $30.69. The impact to a portfolio due to this purchase was 0.81%. The holding were 300,000 shares as of .

Casdin Capital, LLC initiated holding in Turning Point Therapeutics Inc. The purchase prices were between $26.67 and $43.63, with an estimated average price of $35.6. The stock is now traded at around $52.28. The impact to a portfolio due to this purchase was 0.23%. The holding were 60,000 shares as of .

Casdin Capital, LLC initiated holding in Stoke Therapeutics Inc. The purchase prices were between $25.53 and $29.17, with an estimated average price of $26.85. The stock is now traded at around $31.92. The impact to a portfolio due to this purchase was 0.23%. The holding were 85,000 shares as of .

Casdin Capital, LLC initiated holding in Orchard Therapeutics PLC. The purchase prices were between $13.2 and $20.63, with an estimated average price of $17.58. The stock is now traded at around $14.08. The impact to a portfolio due to this purchase was 0.13%. The holding were 100,000 shares as of .

Casdin Capital, LLC added to a holding in Codexis Inc by 150.56%. The purchase prices were between $17 and $21.88, with an estimated average price of $19.28. The stock is now traded at around $13.18. The impact to a portfolio due to this purchase was 4.87%. The holding were 5,073,780 shares as of .

Casdin Capital, LLC added to a holding in Invitae Corp by 74.47%. The purchase prices were between $17.37 and $26.27, with an estimated average price of $21.25. The stock is now traded at around $26.44. The impact to a portfolio due to this purchase was 3.6%. The holding were 3,838,388 shares as of .

Casdin Capital, LLC added to a holding in Alnylam Pharmaceuticals Inc by 46.07%. The purchase prices were between $65.86 and $92.79, with an estimated average price of $76.69. The stock is now traded at around $83.35. The impact to a portfolio due to this purchase was 1.39%. The holding were 650,000 shares as of .

Casdin Capital, LLC added to a holding in Agios Pharmaceuticals Inc by 47.76%. The purchase prices were between $46.17 and $68.1, with an estimated average price of $53.41. The stock is now traded at around $43.46. The impact to a portfolio due to this purchase was 0.75%. The holding were 495,000 shares as of .

Casdin Capital, LLC added to a holding in Homology Medicines Inc by 112.86%. The purchase prices were between $18.35 and $30.34, with an estimated average price of $21.81. The stock is now traded at around $17.95. The impact to a portfolio due to this purchase was 0.72%. The holding were 745,000 shares as of .

Casdin Capital, LLC added to a holding in Gritstone Oncology Inc by 57.95%. The purchase prices were between $9.2 and $15.7, with an estimated average price of $11.46. The stock is now traded at around $10.77. The impact to a portfolio due to this purchase was 0.68%. The holding were 1,770,000 shares as of .

Casdin Capital, LLC sold out a holding in BeiGene Ltd. The sale prices were between $113.99 and $146.86, with an estimated average price of $126.81.

Casdin Capital, LLC sold out a holding in Evolent Health Inc. The sale prices were between $7.71 and $14.54, with an estimated average price of $11.9.

Casdin Capital, LLC sold out a holding in Gilead Sciences Inc. The sale prices were between $61.87 and $69.38, with an estimated average price of $65.76.